Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
复制标题
通过剂量和给药时间表调节 HIV-1MN 重组 gp160 疫苗的免疫反应。
DOI：
10.1016/s0264-410x(97)80003-5
复制
发表时间：
1998
期刊：
影响因子：
5.5
通讯作者：
Eibl,MM
中科院分区：
文献类型：
--
作者：
Gorse,GJ;McElrath,MJ;Matthews,TJ;Hsieh,RH;Belshe,RB;Corey,L;Frey,SE;Kennedy,DJ;Walker,MC;Eibl,MM
采用析因设计的双盲研究，在健康、未感染志愿者中检测HIV-1 MN重组gp 160（MN rgp 160）疫苗的安全性和免疫原性。通过随机分配，20名志愿者在第0、28和168天或第0、56和224天接受三次200 μg剂量的MN rgp 160，4名志愿者接受安慰剂。在24名志愿者中，16名在第532天（第18个月）接受了200 μg或800 μg的MN rgp 160，2名接受了安慰剂。疫苗是安全的。通过Th 1细胞因子产生和淋巴细胞增殖以及血清抗MN rgp 160 IgG（所有亚类）和伊加抗体测量，它诱导T细胞记忆。20名接种者中有15人产生了中和抗体。包括在第0、28和168天免疫接种，随后是800 μg第四剂的方案是最具免疫原性的。
The safety and immunogenicity of HIV-1MNrecombinant gp160 (MN rgp160) vaccine in healthy, uninfected volunteers was tested in a double-blind study with a factorial design. By random assignment, 20 volunteers received three 200 μg doses of MN rgp160 and four volunteers received placebo at days 0, 28, and 168 or 0, 56, and 224. Of the 24 volunteers, 16 received 200 μg or 800 μg of MN rgp160 and two received placebo at day 532 (month 18). The vaccine was safe. It induced T cell memory measured by Th1 cytokine production and lymphocyte proliferation, and serum anti-MN rgp160 IgG (all subclasses) and IgA antibodies. Fifteen of 20 vaccinees developed neutralizing antibody. The regimen including immunizations on days 0, 28, and 168 followed by the 800 μg fourth dose was most immunogenic.